Dr. Yong Tang’s practice focuses on biotechnology and life science, particularly in the pharmaceutical products (e.g., small molecules, oncolytic virus therapy, biologics, monoclonal antibodies, and antibody-drug conjugates) and medical devices (e.g., navigational bronchoscopy, intratumoral drug injection, microneedles, autoinjector, wearable drug delivery device, robotic-assisted surgery, drug-coated implants and sustained drug release). He also has over 12 years of IP and technology consulting experience spanning across the areas of consumer goods, food and beverage ingredients, biopolymers, antibody discovery, robotic surgery and telehealth.

Prior to joining Cantor Colburn, Dr. Tang managed a range of IP consulting projects, including patentability and prior art search, IP landscaping, patent portfolio analysis, competitive intelligence, due diligence investigations, partnership identification, technology scouting, evaluation, and licensing. He has extensive experience in IP searches, utilizing a variety of methods including keywords, patent classifications, gene sequences, citations, and corporate tree. He directed technical intelligence projects for corporations, research institutions, and economic development entities. Dr. Tang, an IBM-certified data scientist, leveraged his expertise in IP data mining and big data analytics to uncover technology trends and identify key commercialization and licensing opportunities. His work focused on translating complex datasets into actionable insights, enabling strategic decisions in intellectual property and technology management.

In addition to his IP practice, Dr. Tang was a prolific research scientist and spent seven years in cancer research on drug combination-mediated synergistic cancer treatment, drug-metabolizing enzyme and transporter-mediated multidrug resistance, and G protein-coupled receptor (GPCR) involved apoptosis and autophagy in colon cancer. Yong is the author or co-author of more than twenty peer-reviewed research articles and gave more than fifteen presentations in national or international conferences. The NIH-National Cancer Institute (NCI) funded Dr. Tang, with the Ruth L. Kirschstein National Research Service Award (NRSA) and Institutional Research Training Grants. Fluent in both English and Mandarin, Dr. Tang brings a unique interdisciplinary approach to his practice.

Professional Affiliations

• The Chinese Antibody Society
• American Association for the Advancement of Science (AAAS)
• Strategic Consortium of Intelligence Professionals (SCIP)
• Intellectual Property Owners Association (IPO)